We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
CD BioGlyco excels in the field of glycoscience, armed with the Glyco™ Vaccine Development Service Platform, which is dedicated to producing Tumor-associated Carbohydrate Vaccine.
GM2, a branched tetrasaccharide with a sialic-acid-terminated structure, is found on the surfaces of various human cancers, including neuroectodermal-origin cancers like melanoma, sarcoma, and neuroblastoma, as well as epithelial cancers such as breast and prostate cancers.
This widespread expression of GM2 on different cancer types makes it an interesting target for developing a potentially universal anticancer vaccine. Furthermore, clinical studies have demonstrated a strong association between elevated levels of anti-GM2 IgM antibodies and improved survival in melanoma patients. The passive administration of anti-GM2 monoclonal antibodies shows promise in achieving favorable outcomes, such as tumor regression. Similarly, active immunity acquired through vaccination can also lead to extended disease-free intervals. The positive clinical results have sparked the pursuit of GM2-based anticancer vaccines.
Fig.1 Schematic overview of the ganglioside structure and biosynthesis. (van der Haar Àvila, et al., 2023)
We provide a chemical synthesis method that possesses flexibility in functionalizing the antigen for immunological investigations.
To synthesize GM2 tetrasaccharide 1, which has a reducing end-free amine, we first perform regioselective sialylation of the lactosyl diol acceptor 2 using sialyl donor 3. This is followed by glycosylation of the 4’-OH with galactosamine (GalN) donor 4.
Fig.2 Retrosynthetic analysis of GM2 tetrasaccharide 1. (CD BioGlyco)
Fig.3 Synthesis of GM2. (CD BioGlyco, 2023)
Subsequently, we use the GM2 glycan obtained to prepare the GM2 conjugate vaccine by attaching the glycan to the carrier VLP bacteriophage Qβ. Previous research has shown that Qβ is more effective than other VLP platforms in boosting immunity. Isothiocyanate chemistry is employed to introduce the GM2 glycan onto Qβ, resulting in the Qβ-GM2 conjugate. This conjugate is capable of inducing high levels of anti-GM2 antibodies, particularly IgG2 antibodies. These antibodies show the ability to bind GM2-expressing tumor cells and exhibit complement-dependent cytotoxicity, leading to the lysis of the tumor cells. These findings demonstrate that bacteriophage Qβ can serve as an effective vaccine platform for a GM2-based vaccine. We are currently conducting further research to optimize the structure of the GM2 antigen and the vaccine construct to enhance vaccine efficacy.
From the initial identification of key targets to the development of intricate vaccine formulations, CD BioGlyco adheres to a rigorous and comprehensive approach. Our team of experts, advanced technology, and innovative approach set us apart. We excel at identifying key targets and formulating effective vaccines. If you have any interest in what we offer, please contact us.
References
About Us
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy